Mirikizumab Pregnancy Registry (I6T-MC-B006)

Study identification

• EU PAS number:
  EUPAS107688
• Study ID:
  107689
• Official title and acronym:
  Mirikizumab Pregnancy Registry (I6T-MC-B006)
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study description:
  Mirikizumab Pregnancy Registry
• Study status:
  Planned

Research institutions and networks

Institutions

Eli Lilly and Company

Study timelines

Date when funding contract was signed

Actual: 05/12/2023

Study start date

Planned: 31/03/2025

Date of final study report

Planned: 31/12/2035

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Eli Lilly &amp, Co.

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable